Timber Pharmaceuticals’ candidate for rare skin disorder flunks all endpoints in late-stage trial
Dermatology biotech Timber Pharmaceuticals’ Phase 3 trial investigating its treatment in a rare inherited skin disorder missed all primary and secondary endpoints, the company announced